Adult Angelman mice get some benefit from boosting UBE3A gene expression
The treatment eases the animals’ sleep troubles, suggesting it has clinically meaningful effects beyond what was thought to be a critical window in early life.
The treatment eases the animals’ sleep troubles, suggesting it has clinically meaningful effects beyond what was thought to be a critical window in early life.
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
To include more autistic people in research, here’s what scientists need to know about informed consent procedures for study participants who have impaired decision-making capacity.
The measure breaks the behaviors down into eight distinct subdomains — categorization that could prove useful for clinical trials, its creator says.
A meeting in Texas reckons with the future of treatment, following two setbacks in 2020.
A new analysis package enables researchers to distill multiple measures of Angelman syndrome mice into a single ‘severity score.’
The pair’s new guidebook offers practical steps to make clinical trials easier and more meaningful for autistic participants.
Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.
The code may help scientists identify people with the autism-linked condition and recruit them into clinical trials.
Oxytocin therapies have failed to consistently benefit autistic people, but their effects in people with two autism-linked conditions may yield new insights, experts argue.